New challenges for private benefits plan

By Staff | March 16, 2015 | Last updated on March 16, 2015
1 min read

Manulife has appointed Dr. Laureen Rance as its first-ever director of Pharmaceutical Relations. Her appointment is part of the company’s new strategy to tackle insurance coverage challenges related to both the cost and accessibility of prescription drugs.

“The increasing prevalence of high-cost specialty drugs will impact the sustainability of private drug plans,” says Lisa Callaghan, assistant vice-president of Group Benefits Product at Manulife. With Rance’s help, “Manulife will work with pharmaceutical manufacturers to help […] employer sponsored benefit plans access valuable and innovative drugs, with the right support, at a prudent cost.”

Rance has more than twenty years of experience working in healthcare; she began her career as a staff pharmacist in retail and hospital settings. Then, she worked as a reimbursement strategist, and in pharmacy benefits management.

For more on healthcare, read:

What’s driving the healthcare sector?

What the right-to-die ruling means for PoAs

How to tackle biotech investing staff


The staff of have been covering news for financial advisors since 1998.